MRK · Merck & Co Inc.
AI read · Good for MRK
The AI's read
The trial results strengthen the case for studying tulisokibart as a treatment for hidradenitis suppurativa, but they do not show it will reach patients. More treated patients reported side effects, and the low dose did not improve quality-of-life scores. The main response measure improved at both active doses, and Merck described safety as comparable to placebo, so the results lean positive.